Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models

References

• Callahan MK. Immune Checkpoint Therapy in Melanoma. Cancer J. 2016;22(2):73–80. doi:10.1097/PPO.0000000000000183. PMID:27111901.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030. PMID:26027431.
   PubMed Web of Science ®Google Scholar
• Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016;34(8):871–8. doi:10.1200/JCO.2015.62.9345. PMID:26811525.
   PubMed Web of Science ®Google Scholar
• O'Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81. doi:10.1016/j.ctrv.2016.11.007. PMID:27951441.
   PubMed Web of Science ®Google Scholar
• Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286–301. doi:10.1038/nrc.2017.17. PMID:28338065.
   PubMed Web of Science ®Google Scholar
• Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017;45:43–51. doi:10.1016/j.coi.2017.01.002.
   PubMed Web of Science ®Google Scholar
• Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22(4):807–12. doi:10.1158/1078-0432.CCR-14-3175. PMID:26515495.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143–58. doi:10.1038/nrclinonc.2015.209. PMID:26598942.
   PubMed Web of Science ®Google Scholar
• de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, et al. Dendritic cell vaccination for metastatic melanoma. Melanoma Res. 2017;27(4):351–7. doi:10.1097/CMR.0000000000000356. PMID:28654547.
   PubMed Web of Science ®Google Scholar
• Cafri G, Sharbi-Yunger A, Tzehoval E, Alteber Z, Gross T, Vadai E, Margalit A, Gross G, Eisenbach L. mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity. Mol Ther. 2015;23(8):1391–400. doi:10.1038/mt.2015.90. PMID:25997427.
   PubMed Web of Science ®Google Scholar
• Sharbi-Yunger A, Grees M, Tzehoval E, Utikal J, Umansky V, Eisenbach L. mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. Oncoimmunology. 2016;5(6):e1160183. doi:10.1080/2162402X.2016.1160183. PMID:27471629.
   PubMed Web of Science ®Google Scholar
• Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 2017;9(2):137–53. doi:10.15252/emmm.201606857. PMID:28028012.
   PubMed Web of Science ®Google Scholar
• Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544–52. doi:10.1038/ng.356. PMID:19282848.
   PubMed Web of Science ®Google Scholar
• Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene. 1998;17(14):1885–8. doi:10.1038/sj.onc.1202077. PMID:9778055.
   PubMed Web of Science ®Google Scholar
• Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A. 2011;108(41):17111–6. doi:10.1073/pnas.1108121108. PMID:21969559.
   PubMed Web of Science ®Google Scholar
• Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin G V, Shurin MR, Umansky V. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol. 2013;190(5):2464–71. doi:10.4049/jimmunol.1202781. PMID:23359505.
   PubMed Web of Science ®Google Scholar
• Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho H-I, Jaenisch R, Celis E, Ploegh HL. Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. Cancer Immunol Res. 2013;1(2):99–111. doi:10.1158/2326-6066.CIR-13-0047. PMID:24459675.
   PubMed Web of Science ®Google Scholar
• Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI : database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3–4):213–9. doi:10.1007/s002510050595. PMID:10602881.
   PubMed Web of Science ®Google Scholar
• Cafri G, Amram E, Rinott G, Koifman G, Fishman S, Keisari Y, Tzehoval E, Margalit A, Eisenbach L, Gross G. Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene. Int Immunol. 2011;23(7):453–61. doi:10.1093/intimm/dxr033. PMID:21652516.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Okada K, Omori T, Sugimura K, Miyata H, Ohue M, Kobayashi S, Takahashi H, Nakano H, Mochizuki C, et al. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017;50(5):1655–62. doi:10.3892/ijo.2017.3955. PMID:28393243.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. doi:10.1038/nature22991. PMID:28678778.
   PubMed Web of Science ®Google Scholar
• Cho H-I, Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 2009;69(23):9012–9. doi:10.1158/0008-5472.CAN-09-2019. PMID:19903852.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol Res. 2017;5(1):3–8. doi:10.1158/2326-6066.CIR-16-0297. PMID:28052991.
   PubMed Web of Science ®Google Scholar
• Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94(1):41–53. doi:10.1189/jlb.1212631. PMID:23667165.
   PubMed Web of Science ®Google Scholar
• Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res. 2013;1(3):145–9. doi:10.1158/2326-6066.CIR-13-0102. PMID:24777676.
   PubMed Web of Science ®Google Scholar
• Bender C, Hassel JC, Enk A. Immunotherapy of Melanoma. Oncol Res Treat. 2016;39(6):369–76. doi:10.1159/000446716. PMID:27259558.
   PubMed Web of Science ®Google Scholar
• Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology. 2017;6(7):e1328341. doi:10.1080/2162402X.2017.1328341. PMID:28811970.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautès–Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–34. doi:10.1038/nrclinonc.2017.101. PMID:28741618.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Corthals J, Van Nuffel AMT, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother. 2015;64(3):381–8. doi:10.1007/s00262-014-1642-8. PMID:25548092.
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN. Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacol Rev. 2015;67(4):731–53. doi:10.1124/pr.114.009456. PMID:26240218.
   PubMed Web of Science ®Google Scholar
• Kramps T, Probst J. Messenger RNA-based vaccines: progress, challenges, applications. Wiley Interdiscip Rev RNA. 2013;4(6):737–49. doi:10.1002/wrna.1189. PMID:23893949.
   PubMed Web of Science ®Google Scholar
• Eisenächer K, Steinberg C, Reindl W, Krug A. The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity. Immunobiology. 2007;212(9–10):701–14. doi:10.1016/j.imbio.2007.09.007. PMID:18086372.
   PubMed Web of Science ®Google Scholar
• Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, Pen J, Bonehill A, Heirman C, Breckpot K, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012;72(7):1661–71. doi:10.1158/0008-5472.CAN-11-2957. PMID:22337996.
   PubMed Web of Science ®Google Scholar
• Wilgenhof S, Van Nuffel AMT, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol. 2013;24(10):2686–93. doi:10.1093/annonc/mdt245. PMID:23904461.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572–6. doi:10.1038/nature14001. PMID:25428506.
   PubMed Web of Science ®Google Scholar
• Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017;28(suppl_12):xii33−43. doi:10.1093/annonc/mdx683. PMID:29253115.
   PubMedGoogle Scholar
• Overwijk WW. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr Opin Immunol. 2017;47:103–9. doi:10.1016/j.coi.2017.07.015. PMID:28806603.
   PubMed Web of Science ®Google Scholar
• Kumai T, Kobayashi H, Harabuchi Y, Celis E. Peptide vaccines in cancer-old concept revisited. Curr Opin Immunol. 2017;45:1–7. doi:10.1016/j.coi.2016.11.001. PMID:27940327.
   PubMed Web of Science ®Google Scholar
• van Stipdonk MJB, Hardenberg G, Bijker MS, Lemmens EE, Droin NM, Green DR, Schoenberger SP. Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol. 2003;4(4):361–5. doi:10.1038/ni912. PMID:12640451.
   PubMed Web of Science ®Google Scholar
• Kannengiesser C, Spatz A, Michiels S, Eychène A, Dessen P, Lazar V, Winnepenninckx V, Lesueur F, Druillennec S, Robert C, et al. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol. 2008;1(4):425–30. doi:10.1016/j.molonc.2008.01.002. PMID:19383316.
   PubMed Web of Science ®Google Scholar
• Polkowska M, Czepielewska E, Kozłowska-Wojciechowska M. Drug Combinations as the New Standard for Melanoma Treatment. Curr Treat Options Oncol. 2016;17(12):61. doi:10.1007/s11864-016-0436-y. PMID:27766547.
   PubMed Web of Science ®Google Scholar
• Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I, Van der Jeught K, Arce F, Guerrero-Setas D, Fernandez-Irigoyen J, et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget. 2014;5(17):7843–57. doi:10.18632/oncotarget.2279. PMID:25151659.
   PubMedGoogle Scholar
• Wu X, Feng QM, Wang Y, Shi J, Ge HL, Di W. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol Immunother. 2010;59(2):279–91. doi:10.1007/s00262-009-0749-9. PMID:19727719.
   PubMed Web of Science ®Google Scholar
• Sevko A, Kremer V, Falk C, Umansky L, Shurin MR, Shurin G V, Umansky V. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol. 2012;9(3):275–81. doi:10.3109/1547691X.2012.655343. PMID:22449053.
   PubMed Web of Science ®Google Scholar
• Gonda K, Shibata M, Ohtake T, Matsumoto Y, Tachibana K, Abe N, Ohto H, Sakurai K, Takenoshita S. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett. 2017;14(2):1766–74. doi:10.3892/ol.2017.6305. PMID:28789407.
   PubMed Web of Science ®Google Scholar
• Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136(10):2352–60. doi:10.1002/ijc.29297. PMID:25353097.
   PubMed Web of Science ®Google Scholar
• Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun. 2017;8:15221. doi:10.1038/ncomms15221. PMID:28537262.
   PubMed Web of Science ®Google Scholar
• van Duikeren S, Fransen MF, Redeker A, Wieles B, Platenburg G, Krebber W-J, Ossendorp F, Melief CJ, Arens R. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol. 2012;189(7):3397–403. doi:10.4049/jimmunol.1201540. PMID:22914049.
   PubMed Web of Science ®Google Scholar
• Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52. doi:10.1126/scitranslmed.aaa4306. PMID:25877890.
   PubMed Web of Science ®Google Scholar
• Ali OA, Lewin SA, Dranoff G, Mooney DJ. Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication. Cancer Immunol Res. 2016;4(2):95–100. doi:10.1158/2326-6066.CIR-14-0126. PMID:26669718.
   PubMed Web of Science ®Google Scholar
• Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21(9):1065–77. doi:10.1093/intimm/dxp072. PMID:19651643.
   PubMed Web of Science ®Google Scholar
• Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung F-T, Kuo CH, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35–45. doi:10.1007/s00432-009-0634-0. PMID:19572148.
   PubMed Web of Science ®Google Scholar
• Lutz MB, Kukutsch N, Ogilvie AL, Roßner S, Koch F, Romani N, Schuler G, Rössner S. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1):77–92. doi:10.1016/S0022-1759(98)00204-X. PMID:10037236.
   PubMed Web of Science ®Google Scholar